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94.78 USD for pregabalin and gabapentin per patient respectively. Total costs per
treatment were 478.15 and 514.73 USD for pregabalin and gabapentin treatments
respectively, representing a cost-saving per patient of 36.58 USD for pregabalin.
CONCLUSIONS: Pregabalin is a cost-saving option compared to gabapentin, repre-
senting a treatment that diminishes the health care system resource utilization
while shortening patient’s length of treatment and reducing the burden related to
other concomitant medications used.
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OBJECTIVES: To model the value of screening for early Parkinson’s Disease (PD). A
model to evaluate lifetime economic value from slowing progression over the
course of PD was adapted to assess sequential olfactory testing and dopamine
transporter (DAT) imaging for screening for pre-motor disease in different patient
groups. METHODS: Data from the PD Associated Risk Study (PARS) were used to
parameterize the model. We assessed screening in patients aged 55 with varying
risk: a general population; persons with a relative with PD; persons with LRRK2
genotype; and persons with REM sleep disorder. PD prevalence per 100,000 at
screeningwas 5, 20, 100 and 200 for these groups. Olfactory test andDAT costswere
$15 and $2500.We assumed that diseasemodifying (DM) therapywas available that
slowed disease progression by 20% at a cost of $35,000. Economic value was mea-
sured in terms of netmonetary benefit (NMB), valuing quality-adjusted life-years at
$50,000. RESULTS: Of those who took the olfactory test, 13.4% yielded positive
results and also took the DAT. The sensitivity and specificity of screeningwere 64%
and 99%. NMB for the four groups was -$211, $217, $2,495, and $5,344, indicating
that screening has positive economic value in personswith a close relativewith PD,
persons with LRRK2 genotype, and persons with REM sleep disorder. Screening
value was positively correlated with rate of progression from preclinical to clinical
PD, efficacy of DM therapy, and preclinical health utility. Screening value was
negatively correlatedwith costs of false positives or false negatives, screening cost,
age at preclinical onset, age at unscreened diagnosis, Hoehn and Yahr stage at
which the unscreened diagnosis is made, and cost of DM therapy. CONCLUSIONS:
Under certain scenarios, particularly in high risk groups, screening for early PD
may be a cost effective strategy.
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OBJECTIVES: To perform a cost-effectiveness analysis of Fingolimod 0.5mg for
Relapsing-RemittingMultiple Sclerosis versus first line treatment options available
in the Public Health Care System in México. METHODS: A Markov model was de-
signed to analyze the cost-effectiveness of Fingolimod vs Glatiramer Acetate and
Interferon- (IFN). The model identifies 5 health-states based on the Expanded
Disability Status Scale. A systematic review was performed to obtain transition
probabilities used in the model. Clinical data for Fingolimod comes from twomain
studies, FREEDOMS and TRANSFORMS, with around 2,186 patients analyzed. Fin-
golimod showed a reduction annualized relapsed rate with fingolimod was signif-
icantly lower (0.18 and 0.20) versus its comparators with placebo and interferones
(0.40 and 0.33). Cycle duration was 1 month, and time horizon 10 years with a
discount rate of 5%. Efficacy was evaluated by QALYs using utility data from inter-
national literature. Directmedical costs include the number of relapses expected in
each of the treatments. Relapses cost are valuated according to the event severity
identified in the DRGs List published by the Mexican Institute of Social Security.
Drug costs are those from public tenders 2011. (US$1MX$13.8). Probabilistic sen-
sitivity analysis (PSA) was performed using Monte Carlo technique. RESULTS: The
expected 10–year costs and QALYs per patient with each treatment were: Fingoli-
mod US$337,994/5.62; IFN-1a6MU US$428,689/1.64; IFN-1a12MU US$468,958/
1.59; IFN-1b8MU US$493,690/1.49; Glatiramer Acetate US$526,444/1.65. PSA
showed Fingolimod was dominant or below the Mexican threshold of 1 PIB per
cápita ( US$8,586) vs all comparators, 85% of the times. Robustness in the results
were confirmed though the sensitivity analysis. CONCLUSIONS: For patients with
Relapsing-Remitting Multiple Sclerosis, treatment with oral Fingolimod is an effi-
cacious and cost-saving option compared with current available options in the
health system. The higher drug acquisition cost of Fingolimod is compensated by
its lower rate of relapse and disability progression.
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OBJECTIVES: Patientswith refractory seizures have highermorbidity andmortality
rates, and poorer quality of life scores, than those with controlled seizures. To
select an adequate therapy aimed to control seizures, decision must be based not
only clinical criteria but also in cost-effectiveness evidence. The objective of this
study is to analyze the cost-effectiveness of lacosamide 200 & 400 mg/d compared
to lamotrigine 300 mg/d and topiramate 200 mg/d as adjunctive therapies for pa-
tientswith uncontrolled partial-onset seizures in Colombia from the health system
perspective. METHODS: An Excel-based, tree-decision model was developed to
assess the cost-effectiveness of the compared therapies. Treatment efficacy was
measured using the proportion of individual with a 50% or greater reduction in
seizure frequency from baseline to maintenance period. Other model parameters
and adverse events rates were extracted from randomized clinical trials identified
through a systematic literature review. Placebo adjustment was performed and
horizon was established as the titration period plus maintenance of 12-weeks.
Direct costs associated with medication, adverse events and cost related to treat-
ment failure were considered. Medications costs were extracted from the 4316-
2011 legislation and procedures’ cost were obtained from the SOAT -2011 formu-
lary. Cost effectiveness ratios were calculated and deterministic sensitivity
analysis was conducted. RESULTS: Higher rates of responders were reported in
lacosamide-400mg(39%) followed by lacosamide-200mg (33%), topiramate-200mg
(31%) and lamotrigine-300mg (24%). Mean cost per patient was lower in lam-
otrigine-300mg and lacosamide-200mg groups, ($668USD;$669USD respectively),
followed by topiramate-200mg ($689USD) and lacosamide-400mg ($818USD). The
cost-effectiveness ratio per responder was favorable for lacosamide-200mg and
lacosamide-400mg ($2.057USD-$2086USD) followed by topiramate-200mg and
lamotrigine-300mg ($2.228USD and $2748USD). The ICER for lacosamide-400mg
was in all cases less than $100USD/additional responder. CONCLUSIONS: The eco-
nomic model demonstrated that lacosamide-200mg and lacosamide-400mg are
cost-effective treatments compared to lamotrigine-300mg and topiramate-200mg
in patients whit uncontrolled partial-onset seizures in Colombia.
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Parkinson’s disease (PD) is a neurodegenerative disease with a variety of clinical
manifestations because of neuronal lost. Formany years levodopahas beenused to
improve dopamine concentrations at the brain; however after a period of benefit,
different limitations appearwith levodopa use, includingmotor complications that
can affect patients’ quality of life. Delaying the use for levodopa and the onset of
motor complications is really important. OBJECTIVES: To compare the cost-effec-
tivenes from a Mexican setting of the use of rasagiline monotherapy vs the use of
pramipexole as treatment strategies in early PD. METHODS: We developed an
economic Markov model to compare information on the effectiveness, utility and
costs of the use of rasagiline and pramipexol over a 5 year period with six-month
cicles. Model input data were obtained fromHaycox et al model and validated in an
expert panel of Mexican Neurologists. Epidemiologic information was obtained
from Mexican Health Minister. The expert panel was developed with a Delphi
method to validate resource utilization, costs and utility of the disease. Costs were
obtained from the Mexican Social Security Institute public lists. Effectiveness out-
comes were time to levodopa, time to levodopa-induced dyskinesia and QALYs.
RESULTS:Rasagilinewas the dominant strategy. Evidence from themodel suggests
that in comparation with pramipexol, early use of rasagiline is associatied with a
healt gain reflected in prolonged time to initiate levodopa by 23.57% through a gain
of 0.796 levodopa-free years; delay in dyskinesia onset by 11.8% (0.49 years); and a
5.4% gain in QALY over a 5- year period. The cost per QALY by year found was MxP
33.400,00 wich is less than a Mexican GDP. Sensivity analyses confirmed that the
model was robust. CONCLUSIONS: The model demostrates that rasagiline is a
cost-effective alternative to pramipexol in the treatment of early PD in Mexico.
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OBJECTIVES: Effective seizure control is integral to treatment of Lennox-Gastaut
syndrome (LGS), a debilitating form of epilepsy characterized by developmental
disorders and frequent drop attacks. In an indirect comparison of antiepileptic
drugs (AEDs) FDA-approved for LGS, clobazam was associated with the greatest
effect size for decreasing drop attacks. We developed an economic model to eval-
uate outcomes and costs of clobazam, from a payer perspective, vs. lamotrigine,
rufinamide, and topiramate as adjunctive therapy for LGS. METHODS: Baseline
seizure frequency (132/month) and AED efficacy were modeled through clinical
trial data. Costs of treating drop seizures were derived from a study of administra-
tive claims data from a large USmanaged health care plan affiliatedwith OptumIn-
sight, with the assumption that 2.3% of drop seizures led to medical care. Seizure
frequency and percentage of patients free of drop seizures were evaluated over a
3-month horizon. Clobazam and rufinamide were also evaluated over 2 years (as-
sumption: 128 seizures/month at baseline). Sensitivity analyses were performed.
RESULTS: Results suggest that LGS patients receiving clobazam had 226 drop sei-
zures over 3 months, compared with 261, 275, and 281 for rufinamide, topiramate,
and lamotrigine, respectively. More than 21% of patients receiving clobazam were
free of drop seizures after 3 months, vs. 5% in each comparator group. Drug and
medical costs for patients receiving clobazam totaled $29,000, vs. $32,000–33,000
for comparators. Clobazam was also more efficacious and less costly than rufin-
amide over a 2-year horizon. Alternative analyses with assumptions of lower rates
of seizures upon discontinuation did not alter conclusions. Assumption that fewer
drop seizures require medical care (0.5% vs. 2.3%) reduced the short-term but not
the long-term cost effectiveness of clobazam. CONCLUSIONS: Medically attended
drop seizures are a major cost driver in LGS. For these LGS patients, clobazammay
be cost-saving.
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